Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.

Related Keywords

Boston ,Massachusetts ,United States ,China ,Beijing ,Japan ,Tavo Espinoza ,Amgen Kyprolis ,Todd Davis ,Paul Hadden ,Matt Hewitt ,Matthew Korenberg ,Lawrence Solow ,Primrose Bio ,Merck Vaxneuvance ,Karen Reeves ,Mattew Korenberg ,Matt Korenberg ,Jazz Pharmaceuticals ,Pfizer ,Exchange Commission ,Craig Hallum Capital Group ,Amgen ,Investment Committee ,Ligand Pharmaceuticals Incorporated ,Ligand Pharmaceuticals Inc ,Call Transcript February ,Pharmaceuticals Incorporated ,Ligand Fourth Quarter ,Chief Financial ,Investor Relations ,Private Securities Litigation Reform Act ,Investor Day ,Viking Therapeutics ,Rich Baxter ,Investment Operations ,Drawbridge Special Opportunities Fund ,Fortress Investment Group ,Hayfin Capital Management ,Clinical Strategy ,Chief Medical Officer ,Global Clinical Submissions ,Pathios Therapeutics ,Craig Hallum Capital ,Travere European ,